Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
Type:
Grant
Filed:
November 19, 2001
Date of Patent:
December 3, 2002
Assignees:
Stanford University Medical Center, Neurocrine Biosciences, Inc.
Inventors:
Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
Abstract: Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Lea and di-sialyl Lea, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Lea and sialyl Lex. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.
Type:
Grant
Filed:
November 23, 1999
Date of Patent:
October 15, 2002
Assignees:
Stanford University
Inventors:
John L. Magnani, Eugene C. Butcher, Ellen L. Berg
Abstract: The present invention provides a method for detecting polymorphisms in a nucleic acid by preconditioning a sample of nucleic acids to completely denature the nucleic acids, e.g., via heating and/or chemical treatment, and performing high-performance liquid chromatography (HPLC) on the nucleic acid under denaturing conditions to identify any polymorphisms. The nucleic acids to be analyzed are completely denatured prior to application of the sample to a stationary reverse-phase support and throughout the HPLC process. Sample elution is also carried out under completely denaturing conditions, and the sample mixture is eluted with a mobile phase containing an ion-pairing reagent and an organic solvent.
Abstract: Compounds having immunomodulatory activity which are peptide-type compounds, or variants or fragments thereof, including the N-terminal acylated and C-terminal amidated or esterified forms of up to 30 amino acids wherein the peptide-type compound comprises the formula:
(a) R aa76-77 L aa79-84 or
(b) aa84-79 L aa77-76 R
wherein:
aa76 is E or V;
aa77 is D, S or N;
aa79 is R or G;
aa80 is I or N;
aa81 is a small or hydrophobic amino acid
aa82 is R or L;
aa83 is G or R;
aa84 is a small or hydrophobic amino acid;
wherein, in said compounds,
at least one of the amino acids is the D isomer
are used by themselves or in combination with immunosuppressant drugs, to reduce CTL activation, particularly in association with transplantation.
Type:
Grant
Filed:
May 22, 1996
Date of Patent:
August 20, 2002
Assignee:
Stanford University (Board of Trustees of the Leland
Standford Junior University)
Abstract: A novel capacitively coupled NDR device can be used to implement a variety of semiconductor circuits, including high-density SRAM cells and power thyristor structures. In one example embodiment, the NDR device is used as a thin vertical PNPN structure with capacitively-coupled gate-assisted turn-off and turn-on mechanisms. An SRAM based on this new device is comparable in cell area, standby current, architecture, speed, and fabrication process to a DRAM of the same capacity. In one embodiment, an NDR-based SRAM cell consists of only two elements, has an 8 F2 footprint, can operate at high speeds and low voltages, has a good noise-margin, and is compatible in fabrication process with main-stream CMOS. This cell significantly reduces standby power consumption compared to other types of NDR-based SRAMs.
Abstract: A novel capacitively coupled NDR device can be used to implement a variety of semiconductor circuits, including high-density SRAM cells and power thyristor structures. In one example embodiment, the NDR device is used as a thin vertical PNPN structure with capacitively-coupled gate-assisted turn-off and turn-on mechanisms. An SRAM based on this new device is comparable in cell area, standby current, architecture, speed, and fabrication process to a DRAM of the same capacity. In one embodiment, an NDR-based SRAM cell consists of only two elements, has an 8 F2 footprint, can operate at high speeds and low voltages, has a good noise-margin, and is compatible in fabrication process with main-stream CMOS. This cell significantly reduces standby power consumption compared to other types of NDR-based SRAMs.
Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lympho-cytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1-X[Fuc&agr;1-y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration and for directing molecules to such sites.
Type:
Grant
Filed:
November 9, 1994
Date of Patent:
May 21, 2002
Assignees:
Stanford University
Inventors:
John L. Magnani, Eugene C. Butcher, Ellen L. Berg
Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1−X[Fuc&agr;1−y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.
Type:
Grant
Filed:
November 9, 1994
Date of Patent:
May 14, 2002
Assignees:
Stanford University
Inventors:
John L. Magnani, Eugene C. Butcher, Ellen L. Berg
Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
Type:
Grant
Filed:
October 20, 1997
Date of Patent:
April 9, 2002
Assignees:
Stanford University Medical Center, Neurocrine Biosciences, Inc.
Inventors:
Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
Abstract: A synergistic combination of ligands that interact with death domain receptors, and diterpenoid triepoxides is used to increase tumor cell killing by induction of apoptosis. Ligands useful in the invention include TRAIL, TNF-&agr;, analogs thereof, stabilized multimers thereof, mimetics, etc. Of particular interest are combined therapy with the diterpenoid triepoxides triptolide and derivatives and analogs thereof.
Type:
Grant
Filed:
February 15, 2000
Date of Patent:
December 11, 2001
Assignee:
The Board of Trustees of the Leland Stanford
University
Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.
Type:
Grant
Filed:
April 5, 1999
Date of Patent:
September 18, 2001
Assignee:
Board of Trustees of Leland Stanford University
Inventors:
Russell N. Van Gelder, Mark E. Von Zastrow, Jack D. Barchas, James D. Eberwine
Abstract: A novel capacitively coupled NDR device can be used to implement a variety of semiconductor circuits, including high-density SRAM cells and power thyristor structures. In one example embodiment, the NDR device is used as a thin vertical PNPN structure with capacitively-coupled gate-assisted turn-off and turn-on mechanisms. An SRAM based on this new device is comparable in cell area, standby current, architecture, speed, and fabrication process to a DRAM of the same capacity. In one embodiment, an NDR-based SRAM cell consists of only two elements, has an 8 F2 footprint, can operate at high speeds and low voltages, has a good noise-margin, and is compatible in fabrication process with main-stream CMOS. This cell significantly reduces standby power consumption compared to other types of NDR-based SRAMs.
Abstract: A fabrication process benefits high-density DRAM cells, including four-Gbit cells and beyond. In one embodiment, a poly-Si pillar transistor is formed on top of a trench capacitor with the top of the pillar transistor being directly connected to the bit line. To reduce the process steps, word line formation is achieved by a spacer etch process and a self-aligned process is used for formation of bit line contact using a CMP process. This embodiment reduces necessary layout area and provides improvements in overall device performance.
Abstract: Invertebrate and vertebrate patched genes are provided, including the mouse and human patched genes, as well as methods for isolation of related genes, where the genes may be of different species or in the same family. The patched genes permit production of patched protein and production of antibodies that bind to patched proteins. Having the ability to regulate the expression of the patched gene, allows for the elucidation of embryonic development, cellular regulation associated with signal transduction by the patched gene, the identification of agonist and antagonist to signal transduction, identification of ligands for binding to patched, isolation of the ligands, and assaying for levels of transcription and expression of the patched gene.
Type:
Grant
Filed:
October 20, 1997
Date of Patent:
January 9, 2001
Assignee:
The Board of Trustees of the Leland S. Stanford
University
Inventors:
Matthew P. Scott, Lisa V. Goodrich, Ronald L. Johnson
Abstract: Consistent with one embodiment of the invention, a GPS signal processing system uses a behavior observer to monitor user dynamics and to aid a time-varying-gain filter arranged to perform continuous position and speed estimates. The behavior observer consists of a fast observer and a signal detector. The fast observer tacks user maneuvers. The signal detector compares outputs of the fast observer and the time-varying-gain filter to determine user dynamics and corrects operations of the time-varying-gain filter. Tracking ability is improved without degradation in steady-state position accuracy.
Abstract: Cell-free systems which effect the production of polyketides employing modular polyketide synthases are described. Libraries of new and/or known polyketides may also be produced in cell-free systems employing aromatic PKS, modular PKS or both.
Type:
Grant
Filed:
July 5, 1996
Date of Patent:
June 27, 2000
Assignees:
Stanford University, Brown University
Inventors:
Chaitan Khosla, Rembert Pieper, Guanglin Luo, David E. Cane
Abstract: Described is an automatic control system for land (and possible marine) vehicles based on carrier phase differential GPS (CPGPS). The system relies on CPGPS to determine vehicle position and attitude very precisely (position to within 1 cm and attitude to within 0.1.degree.). A system incorporates a technique to calculate and compensate for antenna motion due to vehicle roll and pitch. One aspect of the system utilizes an intelligent vehicle controller that recognizes and adapts to changing conditions, such as vehicle speed, implements towed by the vehicle, soil conditions, and disturbance level. The system provides the capability to control the vehicle on various paths, including straight lines and arbitrary curves. Also described is a technique for initialization and vehicle control using only a single pseudolite.
Type:
Grant
Filed:
June 20, 1997
Date of Patent:
April 18, 2000
Assignee:
Stanford University
Inventors:
Bradford W. Parkinson, Michael L. O'Connor, Gabriel H. Elkaim, Thomas Bell